Bone Marrow News and Research

RSS

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.

Viewpoints: Health law in 'red and blue' states; OpEds slam Obama compromise on birth control; Illinois' Medicaid disaster

More than one in six Americans younger than 65 could have access to help with their health insurance costs as a result of the health law. Red and blue congressional districts look remarkably similar here. Republican districts have, on average, an estimated 18 percent of the nonelderly people eligible for help with health insurance costs under the reform law. Democratic districts have about the same, 17 percent.

16 Feb 2012

ASH addresses severe shortage of methotrexate drug

As the world's largest professional society concerned with the causes and treatment of blood disorders, many of ASH's more than 16,000 members are on the front lines of dealing with the country's severe shortage of methotrexate, a drug critical in the treatment of children with acute lymphocytic leukemia.

16 Feb 2012

Mass spectroscopy identifies total of 1,210 UCB proteins

Blood tests have been a mainstay of diagnostic medicine since the late 19th century, offering a wealth of information concerning health and disease. Nevertheless, blood derived from the human umbilical cord has yet to be fully mined for its vital health information, according to Rolf Halden, a researcher at Arizona State University's Biodesign Institute.

15 Feb 2012

Machine-learning methods show that patients with severe brain injury could communicate accurately

Only by employing complex machine-learning techniques to decipher repeated advanced brain scans were researchers at NewYork-Presbyterian/Weill Cornell able to provide evidence that a patient with a severe brain injury could, in her way, communicate accurately.

14 Feb 2012

Two studies demonstrate preliminary success of CyBorD in AL amyloidosis

Two studies published today in Blood, the Journal of the American Society of Hematology (ASH), demonstrate preliminary success of an effective multiple myeloma (MM) regimen in patients with AL amyloidosis, a rare and devastating blood disease that results in deposition of damaging abnormal protein in critical organs of the body, including the kidneys, heart, liver, and intestines, and shares some characteristics with MM.

14 Feb 2012

CyBorD regimen shows promise against AL amyloidosis

A Mayo Clinic-led study, published in the American Society of Hematology (ASH) journal Blood found that CyBorD, a triple chemotherapy drug combination that has been successful in helping patients with the blood cancer multiple myeloma, also showed promise in improving the care for patients with the rare blood disease AL amyloidosis.

14 Feb 2012

$OATS procedure superior to microfracture in repairing cartilage defects$

OATS procedure superior to microfracture in repairing cartilage defects

A new study has demonstrated that a procedure wherein healthy cartilage is transplanted to fix an area of damaged cartilage (osteoarticular cartilage transplantation or OATS procedure) is superior to the standard of care for repairing cartilage defects. It is thought that fixing such lesions may ultimately help to prevent the onset of osteoarthritis, and get athletic individuals back to sporting activities reliably.

9 Feb 2012

BioMimetic to launch new bone graft substitute product line at AAOS meeting

BioMimetic Therapeutics, Inc. today announced it will introduce Augmatrix Biocomposite Bone Graft, a new bone graft substitute product line, to surgeons and distributors at its exhibit booth during the American Academy of Orthopedic Surgeons (AAOS) meeting this week in San Francisco, CA.

8 Feb 2012

Genzyme announces four-year data from eliglustat tartrate phase 2 trial on Gaucher disease type 1

Genzyme, a Sanofi company, announced today four-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate.

8 Feb 2012

Novel stem-cell technique to enhance bone growth

A research team led by UC Davis Health System scientists has developed a novel technique to enhance bone growth by using a molecule which, when injected into the bloodstream, directs the body's stem cells to travel to the surface of bones.

7 Feb 2012

Positive data from Chimerix CMX001 Phase 2 study on CMV disease

Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.

6 Feb 2012

Positive results from Chimerix CMX001 study for CMV in hematopoietic stem cell transplant recipients

6 Feb 2012

State developments: Florida hospitals dodge budget bullet

Spending cuts to health programs will be less than half as much as forecast in the Senate budget, that chamber's health-spending chief announced today. Now, the Senate Subcommittee on Health and Human Services Appropriations will have to cut only $390 million from current spending levels, rather than the more-draconian $850 million that had originally been assigned, said Sen. Joe Negron, chair of the panel.

6 Feb 2012

Tennessee Gov. declares February as 'St. Jude Month'

In 1962, St. Jude Children's Research Hospital opened its doors amid an emotionally charged debate regarding how to treat childhood cancer. At that time, few children with the most common form of childhood cancer survived, and many physicians believed treatment was futile. St. Jude physicians and researchers took a radically different approach, and these efforts proved pivotal in changing the way the world treats childhood cancer.

6 Feb 2012

Merck Serono enters development agreement with Threshold for hypoxia-targeted drug

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that a global agreement was signed with Threshold Pharmaceuticals, Inc., South San Francisco, to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug.

3 Feb 2012

Immune cells from healthy individuals effectively kill cancer cells

Immune cells from healthy individuals can be the new immune cure for cancer. This treatment can kill cancer cells without destroying neighbouring cells. The hope is to eradicate cancer for ever.

3 Feb 2012

Intra-arterial technique of stem cell transplantation may enhance functional recovery from TBI

Experiments in brain-injured rats show that stem cells injected via the carotid artery travel directly to the brain, where they greatly enhance functional recovery, reports a study in the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

2 Feb 2012

Ligand announces results from melphalan Phase II study on multiple myeloma

Ligand Pharmaceuticals Incorporated announced that results from the Phase II study of its Captisol-enabled, propylene glycol-free (PG-free) Melphalan program were featured this evening in a poster presentation at the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT) in San Diego.

2 Feb 2012

Progenitor cells have potential to develop into RBCs

A study of the cells that respond to crises in the blood system has yielded a few surprises, redrawing the 'map' of how blood cells are made in the body.

1 Feb 2012

Novartis' Gleevec receives FDA approval for use in patients with CD117-positive GIST

The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors.

1 Feb 2012